Latest Pharma Insights
Finance Watch: Odyssey Funds Its Autoimmune Disease Journey With A $304m IPO
Public Company Edition: Odyssey launched the 11th biopharma IPO in the US for 2026 and will report Phase II results for its lead program in 2027. Also, follow-on offerings raised $805m for Cytokinetics, $375m for Avalo, $350m for Viridian, $300m for Artiva and $299m for Aura.
Scrip - May 8, 2026
Public Company Edition: Odyssey launched the 11th biopharma IPO in the US for 2026 and will report Phase II results for its lead program in 2027. Also, follow-on offerings raised $805m for Cytokinetics, $375m for Avalo, $350m for Viridian, $300m for Artiva and $299m for Aura.
Scrip - May 8, 2026
Deal Watch: GSK Calls On Halozyme’s Enhanze In Cancer ADC Administration
Including coverage of deals involving Esperion/Archimed, Cue/Ascendant Health, OSR Holdings/BCM Europe, Teikoku Seiyaku/Curedisc, Dogwood/PRIDCor and more.
Scrip - May 8, 2026
Including coverage of deals involving Esperion/Archimed, Cue/Ascendant Health, OSR Holdings/BCM Europe, Teikoku Seiyaku/Curedisc, Dogwood/PRIDCor and more.
Scrip - May 8, 2026
BridgeBio Expects Continued Strength from Attruby
The company reported first quarter sales for the ATTR-CM drug that came in slightly above expectations while highlighting launch preparations for additional products.
Scrip - May 8, 2026
The company reported first quarter sales for the ATTR-CM drug that came in slightly above expectations while highlighting launch preparations for additional products.
Scrip - May 8, 2026
More Resources, More Harm: Medical Device Cyberattacks Worsen Despite Defenses
New survey data exposes a deepening paradox: healthcare organizations are taking security more seriously than ever, yet cyberattacks on medical devices are becoming more frequent and more damaging to patient care.
Medtech Insight - May 8, 2026
New survey data exposes a deepening paradox: healthcare organizations are taking security more seriously than ever, yet cyberattacks on medical devices are becoming more frequent and more damaging to patient care.
Medtech Insight - May 8, 2026
White House’s Revealing Response To Reports Of Makary’s Imminent Ouster
A White House spokesperson provided Medtech Insight with a vague response to multiple reports suggesting Marty Makary’s tenure as US FDA commissioner is coming to an end, while a current reviewer at the agency said Makary’s ouster would be a “disaster.”
Medtech Insight - May 8, 2026
A White House spokesperson provided Medtech Insight with a vague response to multiple reports suggesting Marty Makary’s tenure as US FDA commissioner is coming to an end, while a current reviewer at the agency said Makary’s ouster would be a “disaster.”
Medtech Insight - May 8, 2026
Global Medtech Guidance Tracker: April 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - May 8, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - May 8, 2026
Chiesi Continues Hunt For Rare Disease Drugs After KalVista Acquisition
Scrip spoke with rare disease head Giacomo Chiesi about buying KalVista and its HAE drug, the abundance of rare diseases opportunities and his hope that more companies enter the space.
Scrip - May 8, 2026
Scrip spoke with rare disease head Giacomo Chiesi about buying KalVista and its HAE drug, the abundance of rare diseases opportunities and his hope that more companies enter the space.
Scrip - May 8, 2026
People On The Move: Appointments At Opella, Bionorica, Enzymatica
A round-up of the latest health and wellness people moves: Opella creates chief sales officer role; Bionorica names Germany head; Enzymatica adds to board of directors.
HBW Insight - May 8, 2026
A round-up of the latest health and wellness people moves: Opella creates chief sales officer role; Bionorica names Germany head; Enzymatica adds to board of directors.
HBW Insight - May 8, 2026
FDA Continues AI Expansion, Launches Updated Elsa Platform
The US FDA has completed the consolidation of its data platform and launched Elsa 4.0, a “significant” upgrade to the AI tool that was installed across the agency last year to streamline workflows and help investigators and reviewers expedite their work.
Medtech Insight - May 8, 2026
The US FDA has completed the consolidation of its data platform and launched Elsa 4.0, a “significant” upgrade to the AI tool that was installed across the agency last year to streamline workflows and help investigators and reviewers expedite their work.
Medtech Insight - May 8, 2026
InflaRx Unveils Izicopan Strategic Shift And $150m Offering
Having previously focused on the potential of the oral complement C5a receptor inhibitor in hidradenitis suppurativa, the German biotech has switched its efforts onto kidney disorders, specifically ANCA-associated vasculitis.
Scrip - May 8, 2026
Having previously focused on the potential of the oral complement C5a receptor inhibitor in hidradenitis suppurativa, the German biotech has switched its efforts onto kidney disorders, specifically ANCA-associated vasculitis.
Scrip - May 8, 2026
BsUFA IV Talks Begin With Supplement, Fee System Streamlining Proposals
US FDA and the biosimilars industry want to reduce supplement categories, including some review times, as well as eliminate some fees during the next program cycle.
Generics Bulletin - May 8, 2026
US FDA and the biosimilars industry want to reduce supplement categories, including some review times, as well as eliminate some fees during the next program cycle.
Generics Bulletin - May 8, 2026
Fractyl Health’s CEO On How Revita Plans To Solve The Post-GLP-1 Weight-Regain Puzzle
With more than half of GLP-1 users quitting within a year — and weight rebounding fast —Fractyl Health is betting on a one?time duodenal procedure to lock in metabolic gains. Pivotal data are due in early Q4 2026.
Medtech Insight - May 8, 2026
With more than half of GLP-1 users quitting within a year — and weight rebounding fast —Fractyl Health is betting on a one?time duodenal procedure to lock in metabolic gains. Pivotal data are due in early Q4 2026.
Medtech Insight - May 8, 2026
Aurobindo’s CuraTeQ Secures Canadian Bevacizumab Approval
Looking to continue expansion of its biosimilars portfolio, Aurobindo has secured Health Canada approval for its Bevqolva version of bevacizumab that is set to challenge Avastin – along with several other rivals already in the market.
Generics Bulletin - May 8, 2026
Looking to continue expansion of its biosimilars portfolio, Aurobindo has secured Health Canada approval for its Bevqolva version of bevacizumab that is set to challenge Avastin – along with several other rivals already in the market.
Generics Bulletin - May 8, 2026
Executives On The Move: Five CMOs And CFOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Avalyn Pharma, Astellas Pharma and Sino Biopharmaceutical, plus Halozyme gets a new chief financial officer from Johnson & Johnson.
Scrip - May 8, 2026
Recent moves in the industry include changes at the top at Avalyn Pharma, Astellas Pharma and Sino Biopharmaceutical, plus Halozyme gets a new chief financial officer from Johnson & Johnson.
Scrip - May 8, 2026
Who’s Hired? Viatris Begins Search For New CFO
Viatris is looking for a new chief financial officer after the current CFO announced plans to step down. Meanwhile, Alvotech and Sandoz are also waving goodbye to high-level executives at the same time as CNX, Par, Fresenius Kabi and Teva announce appointments.
Generics Bulletin - May 8, 2026
Viatris is looking for a new chief financial officer after the current CFO announced plans to step down. Meanwhile, Alvotech and Sandoz are also waving goodbye to high-level executives at the same time as CNX, Par, Fresenius Kabi and Teva announce appointments.
Generics Bulletin - May 8, 2026
Regulatory Uncertainty Slows EU AI Innovation, Data Suggests
EU has significantly lower AI medical device approvals and clinical trials than the US, study finds.
Medtech Insight - May 8, 2026
EU has significantly lower AI medical device approvals and clinical trials than the US, study finds.
Medtech Insight - May 8, 2026
BioBytes: AI-Related Deals In Q1 ‘26
AI-led biotech dealmaking in Q1FY26 accelerated across financings, IPOs and pharma alliances, signalling a shift from experimentation to scaled deployment.
Scrip - May 8, 2026
AI-led biotech dealmaking in Q1FY26 accelerated across financings, IPOs and pharma alliances, signalling a shift from experimentation to scaled deployment.
Scrip - May 8, 2026
Siemens Healthineers Kicks Off Diagnostics Carve-Out, Cuts Full-Year Revenue Outlook
Siemens Healthineers has launched a formal process to separate its Diagnostics business and lowered its full-year revenue growth guidance to 4.5–5%, as structural market changes in China pushed down the division's quarterly margin.
Medtech Insight - May 8, 2026
Siemens Healthineers has launched a formal process to separate its Diagnostics business and lowered its full-year revenue growth guidance to 4.5–5%, as structural market changes in China pushed down the division's quarterly margin.
Medtech Insight - May 8, 2026
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - May 8, 2026
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - May 8, 2026
Raynovent May Have Unlocked PDE Inhibitors For MASH
ZSP1601, a pan-PDE inhibitor from China’s Raynovent Biotech, delivered positive results in a Phase IIb trial in metabolic dysfunction-associated steatohepatitis with fibrosis. But the molecule’s capability to resolve MASH remains unclear.
Scrip - May 8, 2026
ZSP1601, a pan-PDE inhibitor from China’s Raynovent Biotech, delivered positive results in a Phase IIb trial in metabolic dysfunction-associated steatohepatitis with fibrosis. But the molecule’s capability to resolve MASH remains unclear.
Scrip - May 8, 2026
Getting Medtech Right In A Small Country
Gwyn Tudor, head of the MediWales forum, lays out the challenges, opportunities and funding on offer for healthtech founders who make Wales part of their strategic plan.
In Vivo - May 8, 2026
Gwyn Tudor, head of the MediWales forum, lays out the challenges, opportunities and funding on offer for healthtech founders who make Wales part of their strategic plan.
In Vivo - May 8, 2026
How The Tailwind Of AI Is Taking Cardiovascular Healthtech Convergence To New Levels
Israel-based global healthtech innovation expert Gilad Glick previews a Biomed Israel 2026 session on how convergence of health technologies and AI-driven risk prediction are transforming cardiovascular medicine.
In Vivo - May 8, 2026
Israel-based global healthtech innovation expert Gilad Glick previews a Biomed Israel 2026 session on how convergence of health technologies and AI-driven risk prediction are transforming cardiovascular medicine.
In Vivo - May 8, 2026
Alcon Bets On New Launches To Offset Cataract Market Challenge
Alcon's Q1 revenue missed estimates as cataract softness and rising competition weighed on implantables. New launches are partially offsetting the pressure, but J&J MedTech's FDA-approved premium IOL entry sharpens the competitive test ahead.
Medtech Insight - May 8, 2026
Alcon's Q1 revenue missed estimates as cataract softness and rising competition weighed on implantables. New launches are partially offsetting the pressure, but J&J MedTech's FDA-approved premium IOL entry sharpens the competitive test ahead.
Medtech Insight - May 8, 2026
Synthon Invests In R&D Expansion
Synthon has announced an investment in expanding its R&D capabilities to support API development.
Generics Bulletin - May 8, 2026
Synthon has announced an investment in expanding its R&D capabilities to support API development.
Generics Bulletin - May 8, 2026
IFF’s Scent Division Grew 6% In Q1; Ulta Strikes Deal With Uber
IFF reaffirmed its full-year 2026 guidance during a first quarter earnings presentation May 5.
HBW Insight - May 8, 2026
IFF reaffirmed its full-year 2026 guidance during a first quarter earnings presentation May 5.
HBW Insight - May 8, 2026
US Consumer Health News Digest: Business, Regulation, Science
Costs, inflation mark earnings reports; logical approach best for cough/cold predictions; CRN’s ‘Sergeant Searchlight’ illuminates supplement product listing; and soccer great Beckham’s supplement brand partners with Inter Miami.
HBW Insight - May 8, 2026
Costs, inflation mark earnings reports; logical approach best for cough/cold predictions; CRN’s ‘Sergeant Searchlight’ illuminates supplement product listing; and soccer great Beckham’s supplement brand partners with Inter Miami.
HBW Insight - May 8, 2026
Finance Watch: Odyssey Funds Its Autoimmune Disease Journey With A $304m IPO
Public Company Edition: Odyssey launched the 11th biopharma IPO in the US for 2026 and will report Phase II results for its lead program in 2027. Also, follow-on offerings raised $805m for Cytokinetics, $375m for Avalo, $350m for Viridian, $300m for Artiva and $299m for Aura.
Scrip - May 8, 2026
Public Company Edition: Odyssey launched the 11th biopharma IPO in the US for 2026 and will report Phase II results for its lead program in 2027. Also, follow-on offerings raised $805m for Cytokinetics, $375m for Avalo, $350m for Viridian, $300m for Artiva and $299m for Aura.
Scrip - May 8, 2026
Deal Watch: GSK Calls On Halozyme’s Enhanze In Cancer ADC Administration
Including coverage of deals involving Esperion/Archimed, Cue/Ascendant Health, OSR Holdings/BCM Europe, Teikoku Seiyaku/Curedisc, Dogwood/PRIDCor and more.
Scrip - May 8, 2026
Including coverage of deals involving Esperion/Archimed, Cue/Ascendant Health, OSR Holdings/BCM Europe, Teikoku Seiyaku/Curedisc, Dogwood/PRIDCor and more.
Scrip - May 8, 2026
BridgeBio Expects Continued Strength from Attruby
The company reported first quarter sales for the ATTR-CM drug that came in slightly above expectations while highlighting launch preparations for additional products.
Scrip - May 8, 2026
The company reported first quarter sales for the ATTR-CM drug that came in slightly above expectations while highlighting launch preparations for additional products.
Scrip - May 8, 2026
Chiesi Continues Hunt For Rare Disease Drugs After KalVista Acquisition
Scrip spoke with rare disease head Giacomo Chiesi about buying KalVista and its HAE drug, the abundance of rare diseases opportunities and his hope that more companies enter the space.
Scrip - May 8, 2026
Scrip spoke with rare disease head Giacomo Chiesi about buying KalVista and its HAE drug, the abundance of rare diseases opportunities and his hope that more companies enter the space.
Scrip - May 8, 2026
InflaRx Unveils Izicopan Strategic Shift And $150m Offering
Having previously focused on the potential of the oral complement C5a receptor inhibitor in hidradenitis suppurativa, the German biotech has switched its efforts onto kidney disorders, specifically ANCA-associated vasculitis.
Scrip - May 8, 2026
Having previously focused on the potential of the oral complement C5a receptor inhibitor in hidradenitis suppurativa, the German biotech has switched its efforts onto kidney disorders, specifically ANCA-associated vasculitis.
Scrip - May 8, 2026
Executives On The Move: Five CMOs And CFOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Avalyn Pharma, Astellas Pharma and Sino Biopharmaceutical, plus Halozyme gets a new chief financial officer from Johnson & Johnson.
Scrip - May 8, 2026
Recent moves in the industry include changes at the top at Avalyn Pharma, Astellas Pharma and Sino Biopharmaceutical, plus Halozyme gets a new chief financial officer from Johnson & Johnson.
Scrip - May 8, 2026
BioBytes: AI-Related Deals In Q1 ‘26
AI-led biotech dealmaking in Q1FY26 accelerated across financings, IPOs and pharma alliances, signalling a shift from experimentation to scaled deployment.
Scrip - May 8, 2026
AI-led biotech dealmaking in Q1FY26 accelerated across financings, IPOs and pharma alliances, signalling a shift from experimentation to scaled deployment.
Scrip - May 8, 2026
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - May 8, 2026
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Scrip - May 8, 2026
Raynovent May Have Unlocked PDE Inhibitors For MASH
ZSP1601, a pan-PDE inhibitor from China’s Raynovent Biotech, delivered positive results in a Phase IIb trial in metabolic dysfunction-associated steatohepatitis with fibrosis. But the molecule’s capability to resolve MASH remains unclear.
Scrip - May 8, 2026
ZSP1601, a pan-PDE inhibitor from China’s Raynovent Biotech, delivered positive results in a Phase IIb trial in metabolic dysfunction-associated steatohepatitis with fibrosis. But the molecule’s capability to resolve MASH remains unclear.
Scrip - May 8, 2026
More Resources, More Harm: Medical Device Cyberattacks Worsen Despite Defenses
New survey data exposes a deepening paradox: healthcare organizations are taking security more seriously than ever, yet cyberattacks on medical devices are becoming more frequent and more damaging to patient care.
Medtech Insight - May 8, 2026
New survey data exposes a deepening paradox: healthcare organizations are taking security more seriously than ever, yet cyberattacks on medical devices are becoming more frequent and more damaging to patient care.
Medtech Insight - May 8, 2026
White House’s Revealing Response To Reports Of Makary’s Imminent Ouster
A White House spokesperson provided Medtech Insight with a vague response to multiple reports suggesting Marty Makary’s tenure as US FDA commissioner is coming to an end, while a current reviewer at the agency said Makary’s ouster would be a “disaster.”
Medtech Insight - May 8, 2026
A White House spokesperson provided Medtech Insight with a vague response to multiple reports suggesting Marty Makary’s tenure as US FDA commissioner is coming to an end, while a current reviewer at the agency said Makary’s ouster would be a “disaster.”
Medtech Insight - May 8, 2026
Global Medtech Guidance Tracker: April 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - May 8, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - May 8, 2026
FDA Continues AI Expansion, Launches Updated Elsa Platform
The US FDA has completed the consolidation of its data platform and launched Elsa 4.0, a “significant” upgrade to the AI tool that was installed across the agency last year to streamline workflows and help investigators and reviewers expedite their work.
Medtech Insight - May 8, 2026
The US FDA has completed the consolidation of its data platform and launched Elsa 4.0, a “significant” upgrade to the AI tool that was installed across the agency last year to streamline workflows and help investigators and reviewers expedite their work.
Medtech Insight - May 8, 2026
Fractyl Health’s CEO On How Revita Plans To Solve The Post-GLP-1 Weight-Regain Puzzle
With more than half of GLP-1 users quitting within a year — and weight rebounding fast —Fractyl Health is betting on a one?time duodenal procedure to lock in metabolic gains. Pivotal data are due in early Q4 2026.
Medtech Insight - May 8, 2026
With more than half of GLP-1 users quitting within a year — and weight rebounding fast —Fractyl Health is betting on a one?time duodenal procedure to lock in metabolic gains. Pivotal data are due in early Q4 2026.
Medtech Insight - May 8, 2026
Regulatory Uncertainty Slows EU AI Innovation, Data Suggests
EU has significantly lower AI medical device approvals and clinical trials than the US, study finds.
Medtech Insight - May 8, 2026
EU has significantly lower AI medical device approvals and clinical trials than the US, study finds.
Medtech Insight - May 8, 2026
Siemens Healthineers Kicks Off Diagnostics Carve-Out, Cuts Full-Year Revenue Outlook
Siemens Healthineers has launched a formal process to separate its Diagnostics business and lowered its full-year revenue growth guidance to 4.5–5%, as structural market changes in China pushed down the division's quarterly margin.
Medtech Insight - May 8, 2026
Siemens Healthineers has launched a formal process to separate its Diagnostics business and lowered its full-year revenue growth guidance to 4.5–5%, as structural market changes in China pushed down the division's quarterly margin.
Medtech Insight - May 8, 2026
Alcon Bets On New Launches To Offset Cataract Market Challenge
Alcon's Q1 revenue missed estimates as cataract softness and rising competition weighed on implantables. New launches are partially offsetting the pressure, but J&J MedTech's FDA-approved premium IOL entry sharpens the competitive test ahead.
Medtech Insight - May 8, 2026
Alcon's Q1 revenue missed estimates as cataract softness and rising competition weighed on implantables. New launches are partially offsetting the pressure, but J&J MedTech's FDA-approved premium IOL entry sharpens the competitive test ahead.
Medtech Insight - May 8, 2026
People On The Move: Appointments At Opella, Bionorica, Enzymatica
A round-up of the latest health and wellness people moves: Opella creates chief sales officer role; Bionorica names Germany head; Enzymatica adds to board of directors.
HBW Insight - May 8, 2026
A round-up of the latest health and wellness people moves: Opella creates chief sales officer role; Bionorica names Germany head; Enzymatica adds to board of directors.
HBW Insight - May 8, 2026
IFF’s Scent Division Grew 6% In Q1; Ulta Strikes Deal With Uber
IFF reaffirmed its full-year 2026 guidance during a first quarter earnings presentation May 5.
HBW Insight - May 8, 2026
IFF reaffirmed its full-year 2026 guidance during a first quarter earnings presentation May 5.
HBW Insight - May 8, 2026
US Consumer Health News Digest: Business, Regulation, Science
Costs, inflation mark earnings reports; logical approach best for cough/cold predictions; CRN’s ‘Sergeant Searchlight’ illuminates supplement product listing; and soccer great Beckham’s supplement brand partners with Inter Miami.
HBW Insight - May 8, 2026
Costs, inflation mark earnings reports; logical approach best for cough/cold predictions; CRN’s ‘Sergeant Searchlight’ illuminates supplement product listing; and soccer great Beckham’s supplement brand partners with Inter Miami.
HBW Insight - May 8, 2026
BsUFA IV Talks Begin With Supplement, Fee System Streamlining Proposals
US FDA and the biosimilars industry want to reduce supplement categories, including some review times, as well as eliminate some fees during the next program cycle.
Generics Bulletin - May 8, 2026
US FDA and the biosimilars industry want to reduce supplement categories, including some review times, as well as eliminate some fees during the next program cycle.
Generics Bulletin - May 8, 2026
Aurobindo’s CuraTeQ Secures Canadian Bevacizumab Approval
Looking to continue expansion of its biosimilars portfolio, Aurobindo has secured Health Canada approval for its Bevqolva version of bevacizumab that is set to challenge Avastin – along with several other rivals already in the market.
Generics Bulletin - May 8, 2026
Looking to continue expansion of its biosimilars portfolio, Aurobindo has secured Health Canada approval for its Bevqolva version of bevacizumab that is set to challenge Avastin – along with several other rivals already in the market.
Generics Bulletin - May 8, 2026
Who’s Hired? Viatris Begins Search For New CFO
Viatris is looking for a new chief financial officer after the current CFO announced plans to step down. Meanwhile, Alvotech and Sandoz are also waving goodbye to high-level executives at the same time as CNX, Par, Fresenius Kabi and Teva announce appointments.
Generics Bulletin - May 8, 2026
Viatris is looking for a new chief financial officer after the current CFO announced plans to step down. Meanwhile, Alvotech and Sandoz are also waving goodbye to high-level executives at the same time as CNX, Par, Fresenius Kabi and Teva announce appointments.
Generics Bulletin - May 8, 2026
Synthon Invests In R&D Expansion
Synthon has announced an investment in expanding its R&D capabilities to support API development.
Generics Bulletin - May 8, 2026
Synthon has announced an investment in expanding its R&D capabilities to support API development.
Generics Bulletin - May 8, 2026
Getting Medtech Right In A Small Country
Gwyn Tudor, head of the MediWales forum, lays out the challenges, opportunities and funding on offer for healthtech founders who make Wales part of their strategic plan.
In Vivo - May 8, 2026
Gwyn Tudor, head of the MediWales forum, lays out the challenges, opportunities and funding on offer for healthtech founders who make Wales part of their strategic plan.
In Vivo - May 8, 2026
How The Tailwind Of AI Is Taking Cardiovascular Healthtech Convergence To New Levels
Israel-based global healthtech innovation expert Gilad Glick previews a Biomed Israel 2026 session on how convergence of health technologies and AI-driven risk prediction are transforming cardiovascular medicine.
In Vivo - May 8, 2026
Israel-based global healthtech innovation expert Gilad Glick previews a Biomed Israel 2026 session on how convergence of health technologies and AI-driven risk prediction are transforming cardiovascular medicine.
In Vivo - May 8, 2026